Clinical trialNCT07217067RecruitingPhase 2Interventional

A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation

SponsorNovartis PharmaceuticalsEnrollment165Atrial Fibrillation

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

A randomized, placebo-controlled, participant-and investigator-blinded study to evaluate the efficacy in reducing atrial fibrillation burden as well as the safety, tolerability and pharmacokinetics of PKN605 in participants with atrial fibrillation

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Novartis Pharmaceuticals
Novartis Pharmaceuticals
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

40 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Novartis Investigative Site
Calgary, Alberta, Canada
Recruiting
Novartis Investigative Site
Vancouver, British Columbia, Canada
Recruiting
Novartis Investigative Site
Halifax, Nova Scotia, Canada
Recruiting
Novartis Investigative Site
Hamilton, Ontario, Canada
Recruiting
Novartis Investigative Site
London, Ontario, Canada
Recruiting
Novartis Investigative Site
Newmarket, Ontario, Canada
Recruiting
Novartis Investigative Site
Toronto, Ontario, Canada
Recruiting
Novartis Investigative Site
Toronto, Ontario, Canada
Recruiting
Novartis Investigative Site
Montreal, Quebec, Canada
Recruiting
Novartis Investigative Site
Montreal, Quebec, Canada
Recruiting
Novartis Investigative Site
Montreal, Quebec, Canada
Recruiting
Novartis Investigative Site
Québec, Quebec, Canada
Recruiting
Novartis Investigative Site
Sherbrooke, Quebec, Canada
Recruiting

China

Novartis Investigative Site
Beijing, Beijing Municipality, China
Recruiting
Novartis Investigative Site
Beijing, China
Recruiting
Novartis Investigative Site
Xi'an, China
Recruiting

Germany

Novartis Investigative Site
Bad Homburg, Germany
Recruiting
Novartis Investigative Site
Berlin, Germany
Recruiting
Novartis Investigative Site
Berlin, Germany
Recruiting
Novartis Investigative Site
Hamburg, Germany
Recruiting
Novartis Investigative Site
Hamburg, Germany
Recruiting

Netherlands

Novartis Investigative Site
Arnhem, Gelderland, Netherlands
Recruiting
Novartis Investigative Site
Maastricht, Limburg, Netherlands
Recruiting
Novartis Investigative Site
Delft, South Holland, Netherlands
Recruiting
Novartis Investigative Site
Goes, Zeeland, Netherlands
Recruiting
Novartis Investigative Site
Groningen, Netherlands
Recruiting
Novartis Investigative Site
Veldhoven, Netherlands
Recruiting

Singapore

Novartis Investigative Site
Singapore, Singapore, Singapore
Recruiting
Novartis Investigative Site
Singapore, Singapore
Recruiting
Novartis Investigative Site
Singapore, Singapore
Recruiting

United Kingdom

Novartis Investigative Site
Brighton, East Sussex, United Kingdom
Recruiting
Novartis Investigative Site
Newcastle upon Tyne, Tyne and Wear, United Kingdom
Recruiting
Novartis Investigative Site
Liverpool, United Kingdom
Withdrawn
Novartis Investigative Site
London, United Kingdom
Recruiting

United States

Cardiology Associates of North Ms
Tupelo, Mississippi, United States
James Edgar Stone
Recruiting
Cooper University Hospital
Camden, New Jersey, United States
Andrea Russo
Recruiting
Weill Cornell Medical Center
New York, New York, United States
Jim Way Cheung
Recruiting
Duke Univ Medical Center
Durham, North Carolina, United States
Jonathan Piccini
Recruiting
Intermountain Medical Center
Murray, Utah, United States
Michael Cutler
Recruiting
Swedish Heart and Vascular Clinic
Seattle, Washington, United States
David Lam
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PKN605

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 28 Oct 2025
Primary completion: 9 Sept 2027
Completion: 9 Sept 2027
Last update posted: 31 Jul 2026
Registered enrollment: 165
Registry id: NCT07217067

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.